OncoMatch/Clinical Trials/NCT06059261
Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.
Is NCT06059261 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Envafolimab and recombinant human endostatin combined with chemoradiotherapy for nasopharyngeal carcinoma.
Treatment: Envafolimab and recombinant human endostatin combined with chemoradiotherapy — This is a single-center, prospective, single-arm, phase II clinical study, to evaluate the therapeutic efficacy and safety of envafolimab combined with chemoradiotherapy and recombinant human endostatin in patients with locally advanced nasopharyngeal carcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage III, IVA
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: radiotherapy
Cannot have received: systemic chemotherapy
Cannot have received: immune checkpoint inhibitor
Lab requirements
Blood counts
WBC ≥ 4000/μL, neutrophils ≥ 2.000/μL, hemoglobin ≥ 9 g/dL, platelets ≥ 100,000/μL
Kidney function
serum creatinine < 1.5 × ULN
Liver function
ALT, AST < 1.5 times the upper limit of normal (ULN), total bilirubin < 1.5 × ULN
Hematology: WBC ≥ 4000/μL, neutrophils ≥ 2.000/μL, hemoglobin ≥ 9 g/dL, platelets ≥ 100,000/μL; Liver function: ALT, AST < 1.5 times the upper limit of normal (ULN), total bilirubin < 1.5 × ULN; Renal function: serum creatinine < 1.5 × ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify